Morning Market Gainers

shares surged 49.45 percent to $17.53 following a report of ongoing complete response in choriocarcinoma patient treated with TRC105 in compassionate use Phase 2 clinical trial.

gained 28.05 percent to $4.20. Can Fite Biopharma shares jumped Thursday following announcement of the FDA Fast Track Designation for its CF102 in the treatment of liver cancer.

shares rose 14.77 percent to $2.72. Pro-Dex reported Q4 earnings of $0.02 per share on revenue of $4.1 million.

shares surged 13.25 percent to $6.07. VBL Therapeutics will present complete Phase 2 data on VB-111 in combination with bevacizumab in recurrent GBM at the European Cancer Conference.

shares climbed 7.10 percent to $1.81 after the company updated its full-year forecast. The company cut its capital expenditure and overhead costs guidance. The company increased the lower end of its production forecast.

gained 7.25 percent to $3.70 after the company reported that Nathan and Sandra Kahn will explore possible purchase of the company.

shares jumped 6.05 percent to $2.98 after the company issued an upbeat forecast for the third quarter. The company expected a Q3 loss of $0.07 per share to $0.02 per share, versus analysts' expectations for a loss of $0.23 per share.